ASH 2023 | MRD negativity in NPM1-mutated AML: the influence of co-occurring mutations and FLAG-Ida induction
Jad Othman
• 13 Dec 2023
Jad Othman, MBBS, King’s College and Guy’s & St Thomas’ NHS Foundation Trust, London, UK, discusses factors influencing measurable residual disease (MRD) status in NPM1-mutated acute myeloid leukemia (AML), based on an analysis of the AML17 (ISRCTN55675535) and AML19 (ISRCTN78449203) trials. Patients are less likely to achieve MRD negativity if they have several co-occurring mutations, whereas induction treatment with FLAG-Ida enhances MRD negativity, even in high-risk groups. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
